Fabrication and characterisation of 3D-printed triamcinolone acetonide-loaded polycaprolactone-based ocular implants

Febri Annuryanti, Juan Dominguez Robles, Qonita Kurnia Anjani, Muhammad Faris Adrianto, Eneko Larrañeta, Thakur Raghu Raj Singh*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
47 Downloads (Pure)


Triamcinolone acetonide (TA) is a corticosteroid that has been used to treat posterior segment eye diseases. TA is injected intravitreally in the management of neovascular disorders; however, frequent intravitreal injections result in many potential side effects and poor patient compliance. In this work, a 3D bioprinter was used to prepare polycaprolactone (PCL) implants loaded with TA. Implants were manufactured with different shapes (filament-, rectangular-, and circle-shaped) and drug loadings (5, 10, and 20%). The characterisation results showed that TA was successfully mixed and incorporated within the PCL matrix without using solvents, and drug content reached almost 100% for all formulations. The drug release data demonstrate that the filament-shaped implants (SA/V ratio~7.3) showed the highest cumulative drug release amongst all implant shapes over 180 days, followed by rectangular- (SA/V ratio~3.7) and circle-shaped implants (SA/V ratio~2.80). Most implant drug release data best fit the Korsmeyer–Peppas model, indicating that diffusion was the prominent release mechanism. Additionally, a biocompatibility study was performed; the results showed >90% cell viability, thus proving that the TA-loaded PCL implants were safe for ocular application.
Original languageEnglish
Article number243
Number of pages18
Issue number1
Publication statusPublished - 11 Jan 2023


Dive into the research topics of 'Fabrication and characterisation of 3D-printed triamcinolone acetonide-loaded polycaprolactone-based ocular implants'. Together they form a unique fingerprint.

Cite this